Cipla Limited Earnings Summary — Q4 FY2026

• Net Profit surged downward by over 55% YoY, reflecting a significant contraction in profitability for the quarter.
• Operating Profit Margin hit a multi-year low of 15%, down from 23% in the same quarter last year.
• Revenue witnessed a sequential decline of 7.5%, indicating cooling demand or pricing pressure in key markets.
• Quarterly expenses remained stubbornly high at 5,586 Crores despite the softening of top-line revenue.
• Inventory levels have risen significantly throughout FY26, suggesting potential stock-build or supply chain shifts.
• Depreciation saw a sharp spike to 383 Crores in the latest quarter compared to 309 Crores YoY.
• The balance sheet remains exceptionally strong with low leverage, despite a slight uptick in borrowings to 614 Crores.

Management remains focused on transitioning into a respiratory and lung-health specialist with a 'One-India' strategy and scaling high-complexity generics in North America.

Deteriorating

A sharp drop in margins and TTM profit growth indicates cyclical headwinds or structural pricing pressure in the generic space.

The outlook is tempered by recent margin erosion and competitive pricing in US generics, though long-term prospects are supported by a dominate position in India's respiratory market and a near-net-cash balance sheet.